Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
|Videos|July 12, 2017
Dr. Klein on Precision Medicine for Prostate Cancer
Author(s)Eric Klein, MD
Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.
Advertisement
Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.
The prostate cancer field has entered the precision medicine era, explains Klein. There are now clinically significant tools in all the different spaces in prostate cancer, such as better screening and tests for the tumor.
Advertisement
Related to this article
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5